At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 332 enrolled

Drug / intervention

BMS-813160 +6 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03184870

NCT03184870Phase 2Completed

Compare CT.gov

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb·interventional·Posted Jun 14, 2017·Updated Oct 9, 2025

In Brief

A Phase 2 clinical trial evaluating BMS-813160, Nivolumab, and 5 other interventions for Colorectal Cancer and Pancreatic Cancer. Completed, enrolled 332 participants across 40 sites in 6 countries.

Detailed Summary

The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsColorectal Cancer, Pancreatic Cancer

CountriesAustralia, Belgium, Canada, Germany, Spain, United States

Collaborators--

Timeline

Phase 2CompletedFinished

201820192020202120222023202420252026

First PostedJun 2017

Enrollment StartAug 2017

Primary CompletionApr 2023

Study CompletionJun 2023

TodayJul 2026

First PostedJun 14, 2017

Enrollment StartAug 8, 2017

Primary CompletionApr 6, 2023

Study CompletionJun 14, 2023

TodayJul 2, 2026

Enrollment to primary: 5.7 yearsPosted 9.0 years ago